Expandable Megakaryocyte Cell Lines Enable Clinically Applicable Generation of Platelets from Human Induced Pluripotent Stem Cells  by Nakamura, Sou et al.
Cell Stem Cell
Clinical ProgressExpandable Megakaryocyte Cell Lines
Enable Clinically Applicable Generation of Platelets
from Human Induced Pluripotent Stem Cells
Sou Nakamura,1 Naoya Takayama,1 Shinji Hirata,1 Hideya Seo,1 Hiroshi Endo,1 Kiyosumi Ochi,1 Ken-ichi Fujita,1
Tomo Koike,1 Ken-ichi Harimoto,1 Takeaki Dohda,1 Akira Watanabe,2 Keisuke Okita,2 Nobuyasu Takahashi,3
Akira Sawaguchi,3 Shinya Yamanaka,2 Hiromitsu Nakauchi,4 Satoshi Nishimura,5,6 and Koji Eto1,4,*
1Department of Clinical Application, Center for iPS Cell Research and Application (CiRA), Kyoto University, 606-8507, Japan
2Department of Reprogramming Science, CiRA, Kyoto University, 606-8507, Japan
3Department of Anatomy, Ultrastructural Cell Biology, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan
4Laboratory of Stem Cell Therapy, Center for Stem Cell Biology and Regenerative Medicine, Institute of Medical Science,
The University of Tokyo, Tokyo 108-8639, Japan
5Department of Cardiovascular Medicine, The University of Tokyo, Tokyo 113-8655, Japan
6Department of Cell and Molecular Medicine, Center for Molecular Medicine, Jichi Medical University, Tochigi 329-0498, Japan
*Correspondence: kojieto@cira.kyoto-u.ac.jp
http://dx.doi.org/10.1016/j.stem.2014.01.011SUMMARY
The donor-dependent supply of platelets is fre-
quently insufficient to meet transfusion needs. To
address this issue, we developed a clinically appli-
cable strategy for the derivation of functional plate-
lets from human pluripotent stem cells (PSCs). This
approach involves the establishment of stable
immortalized megakaryocyte progenitor cell lines
(imMKCLs) from PSC-derived hematopoietic pro-
genitors through the overexpression of BMI1 and
BCL-XL to respectively suppress senescence and
apoptosis and the constrained overexpression of
c-MYC to promote proliferation. The resulting
imMKCLs can be expanded in culture over extended
periods (4–5 months), even after cryopreservation.
Halting the overexpression of c-MYC, BMI1, and
BCL-XL in growing imMKCLs led to the production
of CD42b+ platelets with functionality comparable
to that of native platelets on the basis of a range of
assays in vitro and in vivo. The combination of robust
expansion capacity and efficient platelet production
means that appropriately selected imMKCL clones
represent a potentially inexhaustible source of
hPSC-derived platelets for clinical application.
INTRODUCTION
Platelets generated from megakaryocyte (MK) precursors are
vital for the treatment of many hematological diseases and
traumas. Currently, platelets can only be obtained through blood
donation. Fresh single-donor platelets have a short shelf life and
must be maintained with plasma at 20C –24C; they readily lose
clotting activity when pooled from multiple donors and frozen or
warmed to 37C (Bergmeier et al., 2003; Nishikii et al., 2008).
Moreover, repeated transfusion induces the production of anti-bodies against allogenic human leukocyte antigen (HLA) or
human platelet antigen (HPA) on the transfused platelets
(Schiffer, 2001), which renders the patient unresponsive to
platelet transfusion therapy. These supply logistics and practical
limitations represent barriers to the widespread application of
platelets as a resource for patients. In that context, human
induced pluripotent stem cells (hiPSCs) (Takahashi et al., 2007)
could represent a potent alternative source of platelet produc-
tion. Because platelets do not contain nuclei, gamma irradiation
before transfusion could be used to eliminate any residual
contaminating hiPSCs and their derivatives, reducing the risk
of tumorigenesis. Thus, the application of iPSC-based technol-
ogy could potentially yield a consistent supply of HLA- and/or
HPA-matched or even autologous platelets in a way that would
address some of the major roadblocks in the current clinical
approaches to platelet-based therapy.
Our group and another recently demonstrated that hiPSCs
derived from human skin fibroblasts or blood cells or from human
embryonic stem cells (hESCs) can be used to generate platelets
in vitro and that these platelets appeared to function normally
when transfused into mouse models (Takayama et al., 2010;
Lu et al., 2011). However, the yield of platelets was still far below
what would be required to generate even 1 u of platelet concen-
trate for patient transfusion. Recent studies have shown that
self-replicating MK progenitors can be directly generated from
murine hematopoietic stem cells (HSCs) within bone marrow
(BM) in vivo (Yamamoto et al., 2013), but there was no evident
way to sustain long-term self-replication of MK progenitors
in vitro. We previously showed that the activation of c-MYC to
a restricted level below that associated with senescence and
apoptosis induction appears to lead to an increase in platelet
generation (Takayama et al., 2010). In the present study, we
show that co-overexpression of c-MYC and BMI1, a polycomb
complex component that represses the INK4A/ARF gene locus
(Oguro et al., 2006), enables megakaryocytic cell lines (MKCLs)
derived from hiPSCs or hESCs to grow continuously for up to
2 months. A destabilization domain (DD) vector system (Banas-
zynski et al., 2006) enabled us to control exogenous c-MYC
within the appropriate range, leading to successful induction ofCell Stem Cell 14, 535–548, April 3, 2014 ª2014 Elsevier Inc. 535
Figure 1. Induction of a Megakaryocyte Progenitor Cell Line from Human Embryonic Stem Cells and Induced Pluripotent Stem Cells Was
Induced by Restricted Range of c-MYC Overexpression along with BMI1 Overexpression
(A) Scheme for inducing megakaryocyte progenitor cell lines (MKCLs) from human PSCs. The targets for gene transduction are hematopoietic progenitors,
including the CD34+ population.
(B) Representative photomicrograph of cells transduced with vector alone, c-MYC alone, BMI1 alone, or a combination of c-MYC and BMI1 (2003). The scale bar
represents 100 mm.
(C) Numbers of CD41a+ cells after gene manipulation. Hematopoietic progenitor cells (HPCs) within human embryonic stem cell (hESC; KhES-3 clone) sacs were
collected and transduced with noninducible retroviral vectors with vector alone (GFP alone), c-MYC alone, BMI1 alone, or combinations of c-MYC plus p53
knockdown, c-MYC plus ARF knockdown, c-MYC plus BCL-XL, c-MYC plus INK4A/ARF knockdown (blue), or c-MYC plus BMI1 (orange). The combinations of
c-MYC plus BMI1 and c-MYC plus INK4A/ARF knockdown induced exponential growth in CD41a+megakaryocytes (MKs). Results are expressed asmeans from
two to three independent experiments.
(D) Representative image of May-Giemsa-stained MKCLs. The scale bar represents 20 mm.
(legend continued on next page)
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immortalized MKCLs (imMKCLs) that can be grown for more
than 5 months and thus function as candidate cell banks.
When the expression of c-MYC, BMI1, and BCL-XL is turned
off, imMKCLs produce functional CD42b (glycoprotein Ib a
[GPIba] and receptor for von Willebrand factor [vWF])+ platelet
particles. The expression of CD42b on platelets is required for
the initiation of clotting (Ware et al., 2000) and bacterial clearance
in vivo (Wong et al., 2013). Although previous studies have re-
ported that CMK, Meg01, and K562 cells, three well-known
MK lineage leukemia cell lines, can become polyploid and
release CD41a+ particles in the presence of agonist stimulation,
they do not provide a suitable source for a platelet supply
because the particles are CD42b (Isakari et al., 2009; Sato
et al., 1989; Terui et al., 1998). In this report, we describe a strat-
egy that involves MKCLs with long-term self-renewal capacity
and the potential to provide an inexhaustible supply of CD42b+
platelets; in that respect, they resemble endogenous self-repli-
cating MK progenitors identified in vivo (Yamamoto et al.,
2013). Clinical application of this technology could provide a
plentiful supply of platelets from suitably screened and selected
imMKCL clones to serve as cell bank stocks with minimal risk of
adverse side effects.
RESULTS
Induction of Expandable MK Progenitor Cells from
Human PSCs with c-MYC and BMI1
We previously showed that, when expressed at an appropriate
level, c-MYC acts as a growth mediator in normal megakaryo-
poiesis and thrombopoiesis from hESCs or hiPSCs, whereas
excessive c-MYC expression in hematopoietic progenitor cells
(HPCs) induces the activation of the INK4A and ARF pathways,
leading to senescence and apoptosis (Takayama et al., 2010).
Therefore, we hypothesized that c-MYC activation might con-
tribute to self-replication at the MK progenitor stage. When we
assessed the effects of c-MYC overexpression alone, BMI1
overexpression alone, c-MYC overexpression plus p53 knock-
down, c-MYC plus BCL-XL overexpression, and c-MYC plus
BMI1 overexpression in CD34+CD43+-containing HPCs derived
from the KhES-3 hESC line, we found that c-MYC over-
expression alone or the combination of c-MYC and BMI1 over-
expression increased numbers of large cells expressing
megakaryocytic CD41a+CD42a (GPIX)+CD42b+CD9+ markers
over a 2-week period (Figures 1A–1C; Figure S1A available
online). With c-MYC and BMI1 overexpression (Figure 1C,
orange triangles) or c-MYC overexpression and INK4A/ARF
knockdown (Figure 1C, blue triangles), but none of the other
aforementioned conditions, proliferation of this cell population
wasmaintained at an exponential level for 2months (MK progen-
itor cell line; Figure 1C, orange triangles) and was dependent
upon the presence of thrombopoietin (TPO) with the help of(E) Schematic diagram illustrating the hypothesis that there is an association betwe
or hiPSCs) define the c-MYC activation window (restricted range) needed to ind
(F) Scheme for a c-MYC regulation system using a destabilization domain (DD). P
Administration of Shield1 putatively inhibits DD-mediated degradation in a conce
(G) Numbers of CD41a+ MKs determined by flow cytometry. MKs were derived fro
or inducible c-MYC-2A-BMI1 retroviral vector (without [w/o] DD; see Figure S2Astem cell factor (SCF). This suggests that the effect of BMI1
may be to at least inhibit INK4A/ARF-dependent senescence
and apoptosis during the initiation of self-replication, as con-
firmed by quantitative PCR (qPCR) analysis, which revealed
BMI1 represses c-MYC-induced the upregulation of INK4A/
ARF (Figure S1B). The CD41a+ MKCLs derived from hESCs
showed monoblastic morphology with basophilic cytoplasm
(Figure 1D) and generated aberrant platelet-like particles ex-
pressing normal levels of CD41a but reduced levels of CD42b
(Figure S1C). This is consistent with the requirement for the
downregulation of c-MYC for maturation of MKs (Takayama
et al., 2010).
A Defined c-MYC Expression Level Is Important for
MKCL Induction and Robust Expansion
Our ability to induce MKCLs with c-MYC and BMI1 overexpres-
sion and then grow the cells for more than 2 weeks varied among
individual PSC clones (data not shown). Therefore, we sus-
pected that individual PSC clones require different levels of
c-MYC. When we prepared an inducible all-in-one vector
harboring c-MYC and BMI1 (Ohmine et al., 2001) (Figure S1D),
we obtained clearer evidence that c-MYC levels are crucial for
the sustained growth of MKCL, given that we saw different
results with c-MYC-2A-BMI1 and BMI1-2A-c-MYC gene se-
quences in this vector (Figures S1E and S1F). Furthermore, to
confirm the hypothesis that, in some individual PSC clones, the
effective c-MYC expression level may be restricted to a specific
range (Figure 1E), we used a vector tagged with a DD (Banaszyn-
ski et al., 2006) in order to reduce the level of c-MYC protein (Fig-
ure 1F). This system regulates protein stability, and thus the level
of c-MYC expression, in a manner that depends on the Shield1
concentration (NIH 3T3 cells in Figure S1G). When we used
this DD-tagged vector system to establish iPSC (692D2)-derived
MKCLs, we found that 692D2 iPSCs showed no self-replication
when transduced with c-MYC-2A-BMI1 overexpression without
a DD tag, but transduction of the DD tag vector without the addi-
tion of Shield1 allowed clone 692D2 to grow for up to 50 days in
culture (Figure 1G). This self-replication was inhibited by 100 or
1,000 nM Shield1 (Figure 2Ai), suggesting the total c-MYC level
most likely blocked stable self-replication. This result was not
due to nonspecific cell toxicity (Figure S2A) or activation of the
INK4A/ARF gene locus by the high level of c-MYC, given that
levels of p14 and p16 mRNA (derived INK4A/ARF locus gene)
did not differ in the presence or absence of 1,000 nM Shield1
(Figure S2B).
Given that BMI1, which is also overexpressed in our system,
represses the INK4A/ARF gene locus, the mechanism underly-
ing the MYC-dependent failure of continuous self-replication
was unclear. However, the well-known involvement of c-MYC
in caspase-dependent apoptosis (Juin et al., 2002) prompted
us to assess caspase activity in the MKCL clone. Caspase
assays revealed that the activation of caspases 3 and 7 in DDen c-MYC levels andMK self-replication. Individual human PSC clones (hESCs
uce MK self-replication.
roteins with a DD are rapidly destroyed via the ubiquitin-proteasome pathway.
ntration-dependent manner.
m iPSCs (692D2) transduced with inducible c-MYC-DD-2A-BMI1 (with [w] DD)
).
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Figure 2. Later Expression of BCL-XL In-
hibited Caspase Activation Induced by
Excessive c-MYC, Stabilizing Cell Growth
and Contributing to the Establishment of
imMKCLs
(A) Relationship between the c-MYC expression
level, cell viability, and caspase activity. (i)
Numbers of live CD41a+ MKs derived from hiPSC
(692D2)-based MKCLs generated with an induc-
ible DD vector in the absence or presence of the
indicated concentrations of Shield1. (ii) Caspase 3
and 7 activity in samples of Jurkat cells (control,
fold = 1, black bar) or hiPSC (692D2)-derived
MKCLs on day 2 of culture after transduction with
a DD system in the absence or presence of
1,000 nM Shield1. *p < 0.05; **p < 0.01; ***p <
0.001. Results are expressed as means ± SE from
five independent experiments.
(B) Scheme for generating unstable MKCLs with
c-MYC and BMI1 (2F) or imMKCLs with c-MYC,
BMI1, and BCL-XL (3F).
(C and D) Additional transduction of BCL-XL gene
improved the growth curve for CD41a+ MKs
derived from hiPSC (692D2)-derived MKCLs with
a DD system (C; clone 1 [Cl-1]) and from hESCs
(KhES3)-derived MKCLs (D; Cl-2). Yellow circles
indicate the numbers of cells obtainedwith 3F, and
blue circles indicate 2F. Cell numbers were
calculated cumulative values.
(E) Increment in CD41a+ cells derived from Cl-1
and Cl-2 after cryopreservation. Results were an
average of two independent experiments.
(F) The additional effect of p53 knockdown on
immortalization of MKCLs. Results are expressed
as means ± SE from three independent experi-
ments.
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2-fold higher in the presence of 1,000 nM Shield1 than in its
absence. This increased caspase activation was also associated
with reduced cell viability (Figures 2Ai and 2Aii), confirming that
restricting caspase activation may be key to successfully estab-
lishing expandable MKCLs (Figure S2B). Notably, caspase acti-
vation in the absence of Shield1 was still 12.23 higher than in
Jurkat cells (Figure 2Aii). Some apoptotic events are transcrip-
tionally determined (Chen et al., 2007; Kumar and Cakouros,
2004). Therefore, to further address the mechanism by which
excessive c-MYC represses self-replication and induces apo-
ptosis, we carried out a microarray analysis with iPSC-derived
MKCLs treated with or without 1,000 nM Shield1. Gene ontology
classification of genes differentially expressed in the presence
and absence of Shield1 indicated a correlation between higher
levels of c-MYC (1,000 nM Shield1) and the expression of the
proapoptotic factors BMF and BBC3 (PUMA), which can
contribute to the release of cytochrome-c from mitochondria538 Cell Stem Cell 14, 535–548, April 3, 2014 ª2014 Elsevier Inc.via mitochondrial outer membrane per-
meabilization. High levels of c-MYC also
influenced cell-cycle-related genes, in-
creasing the expression of cyclin-depen-
dent kinase inhibitors (CDKN1B, p27, and
Kip1), which could arrest MKCL growth.
These changes were also confirmed byqPCR analysis (Figures S2C and S2D). Thus, high c-MYC
expression can lead to caspase-dependent MKCL apoptosis
(Figure 2A), despite the suppression of the INK4A/ARF pathway
by BMI1 (Figure S2B). These data again indicate that alternative
apoptosis pathways, as well as the INK4A/ARF pathways, are
independently induced by excessive c-MYC in individual PSC-
derived MKCL clones.
Suppression of Caspase Activation through BCL-XL
Expression Promotes Immortalization
We noticed that MKCLs obtained from either ESC clone KhES3
or iPSC clone 692D2 with c-MYC plus BMI1 (Figure 2B, bottom
line) exhibited limited growth potential and discontinuous cell
growth that ceased at about 60 days, potentially reflecting an
increase in caspase activation (692D2 cell growth in Figure 2C;
KhES3 cell growth in Figure 2D; 0 nM Shield1for 692D2 in
Figure 2Ai and KhES-3 in Figure S2E). Thus, it appears that
the expression of c-MYC and BMI1 alone are not suitable for
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examine the effect of BCL-XL on days 14–21 after transduction
of c-MYC plus BMI1 (Figure 2B). We found that BCL-XL overex-
pression induced exponential growth of CD41a+ cells derived
from either 692D2 or KhES3 cells. This growth persisted for
over 5 months, and we therefore deemed these cells to be
self-renewing imMKCLs (Figures 2C and 2D for 692D2 [imMKCL
clone 1, Cl-1], and Figure 2D for KhES-3 ESCs [Cl-2]; yellow
circles). These two imMKCLs also showed comparable growth
after cryopreservation (Figure 2E) as well as somewhat larger
cell size and expression of CD41a, CD42a, CD42b, and CD9
(Figure S2F). Growth of these imMKCLs was sustained even
with higher c-MYC expression in the presence of 100 or
1,000 nM Shield1 (Figures S2G–S2I), and the cells exhibited
comparatively low levels of caspase 3 and 7 activation, similar
to that of Jurkat cells (Figure S2I).
To further validate the function of BCL-XL in caspase regula-
tion, we tested the effect of the caspase inhibitor Z-VAD FMK
on proliferation. Caspase inhibition increased proliferation about
21-fold, whereas BCL-XL expression elicited a 64-fold increase.
In contrast, the vehicle control (DMSO) enhanced apoptosis (Fig-
ures S3A–S3C). Altogether, these findings again confirm that
BCL-XL inhibits apoptosis through caspase 3 and 7 inactivation
and that c-MYC, BMI1, and BCL-XL are all required for the in-
duction of imMKCLs from PSC clones. In addition, because it
is well known that activation of p53 and p21 is also associated
with c-MYC-dependent apoptosis (Hotti et al., 2000), we
assessed the effect of inhibiting p53 on cell growth with imMKCL
Cl-1. Our results show no involvement of p53 in cells expressing
c-MYC, BMI1, and BCL-XL (Figure 2F), and a similar result was
obtained with KhES-3-imMKCL (Cl-2; data not shown).
Next, we asked whether the simultaneous overexpression of
c-MYC, BMI1, and BCL-XL was more suitable for establishing
imMKCLs than overexpression of c-MYC plus BMI1 followed
by later expression of BCL-XL. To address that question, we
used four individual PSC clones to compare two protocols:
simultaneous overexpression of all three genes or overexpres-
sion of c-MYC and BMI1 followed by BCL-XL 14–21 days later,
counting from the HPC stage (days 28–35 from the hESC or
iPSC stage; Figure 2B, top). Simultaneous addition of all
three genes promoted maximal proliferation for only up to
40–50 days, whereas stepwise addition of c-MYC and BMI1 fol-
lowed by BCL-XL consistently showed more sustained prolifer-
ation with all clones examined (Figure S3D–S3G).
One potential caveat to this approach is that long-term cultiva-
tion might lead to imMKCLs becoming oncogenic. Interestingly,
after cultivation for 5 months, two of three imMKCLs, Cl-1 and
Cl-2 but not Cl-7, consistently showed a specific karyotypic
abnormality: chromosomal translocation that included chromo-
some +1 or 5 (Figure S4A). When these two clones were
separately infused into immunodeficient mice, one (n = 5)
displayed leukemogenesis contributing to early death, but the
other did not (Figure S4B). These results highlight the importance
of transplantation studies with imMKCLs for clone selection.
Interestingly, Cl-7 exhibited no karyotypic abnormality (Fig-
ure S4A) and consistently showed no abnormalities in transplan-
tation studies (up to 16 weeks; Figure S4B). Therefore, we
suggest that combined analysis, including both karyotypic ex-
amination and transplantation of individual imMKCL clones,would be useful for selecting imMKCLs as cell bank stock
candidates.
Differentiation Phase of imMKCLs for Upregulation of
CD42b during Maturation
TheGPIb-V-IX complex, particularly CD42b (GPIba), on platelets
is a key binding site for vWF and is required for the initial adhe-
sion of platelets to an injured vessel wall (Ware et al., 2000) as
well as normal circulation after transfusion (Leytin et al., 2004).
Platelets lacking CD42b expression are quickly cleared from
the circulation in vivo, leading to insufficient numbers of circu-
lating platelets after transfusion (Nishikii et al., 2008). Assuming
that the downregulation of c-MYCwould be required for the gen-
eration of CD42b+ platelets (Takayama et al., 2010), we turned
off the expression of all three inducers (c-MYC, BMI1, and
BCL-XL). Five days after these genes were turned off under
serum-free conditions (Figure 3A), the iPSC-derived imMKCLs
had changed to exhibit MK polyploidization (Figure 3B; on,
5.5% [left]; off, 20.2% [right]) as well as proplatelet formation
(Figure 3C and Movie S1) with increased CD42b expression.
This is exemplified by the two imMKCL clones in Figure 3D.
Along with those changes, after turning off the expression
of the exogenous inducing genes, both endogenous and
exogenous c-MYC,BMI1, andBCL-XL expression declined (Fig-
ure S5A), and transcription factors associated with MK matura-
tion, GATA1, FOG1, NFE2, and b1-tubulin increased to levels
comparable to or higher than those seen in cord blood (CB)-
derived MKs (Figure 3E).
Induction of Efficient Yield of CD41a+CD42b+ Platelets
Turning c-MYC, BMI1, and BCL-XL off with a doxycycline-regu-
lated system increased the CD42b+ platelet yield from imMKCLs
and upregulated CD42b expression in CD41a+ platelets (Figures
4A and 4B), in comparison to maintaining the overexpression of
the three factors or BCL-XL alone (Figure S5B). In addition,
whereas imMKCLs generated significant numbers of CD41a+
CD42b+ particles that closely resembled endogenous platelets,
the well-known MKCLs Meg01, CMK, and K562, produced
mostly CD41a+, but CD42b, platelet-like particles (Figure S5C).
We estimated production to be three CD42b+ platelets per Cl-2
imMKCL-MK and 10 platelets per Cl-7 imMKCL-MK after the in-
duction of differentiation (5 days after exogenous expression
was turned off; Figure S5D) under serum-free conditions, which
is a suitable level for clinical application. In a 10-cm dish scale
(10 ml), 4 3 106 and 2 3 106 platelets per ml were obtained
from imMKCL Cl-7 and Cl-2, respectively (Figure 4C). Therefore,
our proposed system could theoretically yield 1011 platelets
(equivalent to one transfusion) within 5 days with 25–50 l
medium.
Characterization of platelet yields using flow cytometry re-
vealed that the expression levels of platelet-functional mole-
cules, including CD42b, CD61 (b3 integrin), protease-activated
receptor 1 (PAR1; thrombin receptor), CD49b (a2 integrin), and
CD29 (b1 integrin), were mostly comparable to those seen in
fresh human peripheral blood (PB)-derived platelets and higher
than in human endogenous pooled platelets, although the
expression of GPVI (GP6) was a little weaker than it was in fresh
PB (Figure 4D), possibly because of receptor shedding at 37C
(Gardiner et al., 2012). At the ultrastructural level, transmissionCell Stem Cell 14, 535–548, April 3, 2014 ª2014 Elsevier Inc. 539
Figure 3. Turning Off 3F Transgenes Pro-
moted the Maturation of MKs from
imMKCLs
(A) MKs and platelets were analyzed 5 days after
turning off 3F (cMYC, BMI1, and BCL-XL)
expression.
(B) Giemsa staining (top pictures) and flow cyto-
metric analysis of ploidy among imMKCLs with
and without 3F expression (genes on or genes off).
The scale bar represents 50 mm.
(C) imMKCL Cl-7 examined with time-lapse
microscopy 4 days after genes were turned off.
Sequential images showing proplatelet formation.
The scale bar represents 50 mm.
(D) Representative contour plots for imMKCL Cl-2
and Cl-7 (MK populations are shown in side and
forward scatter contour plots in a flow cytometer)
derived from ESCs and iPSCs (KhES3 and DN-
SeV2, respectively).
(E) qPCR analysis of GATA1, p45 NF-E2, FOG1,
and b1-tubulin gene expression. Samples were
obtained from hiPSC-derived CD34+/CD43+/
CD41a/GPA HPCs (Sac-HPCs), Sac-depen-
dent MKs from ESCs and iPSCs, MKs derived
from cord blood (CB)-CD34+ cells, and imMKCL
Cl-7 (DN-SeV2 iPSC clone) in the presence (on)
or absence (off) of 3F. Gene expression was
normalized to GAPDH expression. 3F was trans-
duced into Sac-HPCs as described in the Experi-
mental Procedures. Results are expressed as
means ± SE from three independent experiments.
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through cytoplasmic fragmentation (Figure S6A) and proplate-
lets in the culture dish (Figure 3C and Movie S1). Individual
imMKCL-derived platelets showed normal microtubules but
fewer granules when compared to fresh human donor platelets
(Figure 5A and S6A). To explore the functionality of imMKCL-
derived platelets, we used flow cytometry to examine integrin
aIIb3 activation (inside-out signaling) or platelet aggregation after
stimulation with platelet agonists (De Cuyper et al., 2013).
Agonist stimulation increased PAC-1 binding mean fluorescent
intensity, given that this antibody binds to the activated form of
aIIbb3 integrin (Figures 5B and 5C) as well as platelet aggrega-
tion (Figure 5D), clot retraction (Figure 5E), actin cytoskeletal
changes (Figure S6B), and vWF or ADP secretion (Figure S6C).
Collectively, most in vitro functional parameters indicated that
imMKCL platelets gave less robust responses than fresh human
platelets, but, comparison to pooled human endogenous plate-
lets (Figures 5C and 5D) or iPSC-derived platelets generated540 Cell Stem Cell 14, 535–548, April 3, 2014 ª2014 Elsevier Inc.with a direct differentiation method (data
not shown; Takayama et al., 2010) indi-
cated their functionality was still sufficient
to be useful. We also used an ex vivo flow
chamber system within which human
vWF (10 mg/ml) was immobilized and a
shear rate of 1,600 s1 was applied.
imMKCL platelets showed 62.3% (Cl-2)
and 75.8% (Cl-7) of the CD42b-depen-
dent binding of fresh human platelets,
and human CD42b blocking antibodyreversed this adhesion (Figure 5F). With our current protocol,
final platelet collection takes place during the final 5 days in
the absence of serum at 37C. Altogether, these two conditions
may account for the relatively low granule content (Figure S6C)
and diminished aggregation (Figure 5D).
imMKCL-Derived Platelets Show Thrombogenic Activity
in Mouse Models of Thrombocytopenia
Next, we evaluated the in vivo circulation of imMKCL platelets
with previously optimized transfusion models (Takayama et al.,
2010). Using NOD/SCID/IL-2Rg-null (NOG) mice with irradia-
tion-induced thrombocytopenia, flow cytometric analyses were
carried out 30 min, 2 hr, and 24 hr after transfusion (1 or 6 3
108 platelets per mouse). The posttransfusion kinetics of
imMKCL-derived platelets were nearly the same as those ob-
tained with fresh human platelets (n = 4 individual groups in
two independent experiments; Figures 6A and 6B). To further
assess the functionality of imMKCL platelets in vivo, we used
Figure 4. imMKCL-Derived Mature MKs Generated CD41a+CD42b+ Platelets upon Turning Off 3F Transgenes
(A) Representative contour plots for human peripheral blood (PB)-, CB-CD34+HS/PC-, and imMKCL (3F on and off)-derived platelets (platelet population are
shown in side and forward scatter contour plots).
(B) Fold increment inCD42b+mean fluorescent intensity (MFI) amongCD41a+ imMKCLCl-2 (KhES3)- andCl-7 (DN-SeV2)-derived platelets.White bars, genes on;
black bars, genes off. Results are expressed asmeans±SE from three independent experiments. Themean value of the sampleswith genes on is assigned as 1.0.
(legend continued on next page)
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Platelets from Immortalized Megakaryocytesthrombocytopenic NOG mice and high-spatiotemporal-resolu-
tion confocal laser microscopy to visualize the initial adhesion
of individual platelets to laser-exposed vessel walls and the sub-
sequent thrombus formation under flow conditions without
apparent endothelial disruption (Takizawa et al., 2010; Nishimura
et al., 2012). Using fresh human platelets or imMKCL-derived
platelets labeled with carboxyfluorescein diacetate and succini-
midyl ester, along with injection of Texas Red dextran to visu-
alize blood cell kinetics, we calculated the numbers of platelets
adhering to the endothelium after laser injury in the NOG sys-
tem (Movie S2). We confirmed that single imMKCL-derived
platelets adhere to the vessel without forming aggregates
with host platelets. AK4 antibody (antihuman P-selectin) partly
reversed the platelet adhesion (i.e., >60% for Cl-2 platelets;
Figure 6C), indicating that P-selectin contributed to the initial
adhesion of the imMKCL platelets and that endothelial-derived
vWF and P-selectin are relevant in our mouse models (Nishi-
mura et al., 2012). We also confirmed the contribution of these
platelets to thrombi in vivo. We found that platelets from four
different imMKCL clones differentially contributed to the devel-
oping thrombi to a degree that was at a minimum better than
human endogenous pooled platelets (n = 40 vessels from three
to five animals individually, p < 0.0001; Figures 6D and 6E and
Movie S3), suggesting that transfer to in vivo conditions may
further improve the functionality of imMKCL platelets, perhaps
through rejuvenation via endocytosis of granules. Accordingly,
our results suggest that, although imMKCL platelets display a
smaller capacity for adhesion and aggregation than fresh donor
platelets in vitro and in vivo, the functional capacity observed is
at a useful level and could potentially be improved by further
optimization of the culture conditions and/or the collection
method.
DISCUSSION
For successful clinical application of hiPSC technology to
platelet transfusion, it will be necessary to produce very large
quantities of platelets. To achieve this goal, we will need to boost
production efficiency at two stages: the transition from HSCs or
myeloid lineage HPCs to MKs and the transition from MKs to
platelets (Fuentes et al., 2010; Lu et al., 2011; Takayama et al.,
2010; Lambert et al., 2013; Yamamoto et al., 2013). In the pre-
sent report, we focused on a strategy of generating self-renew-
ing immortalized MKs (Yamamoto et al., 2013), and we have
succeeded in establishing imMKCLs with in vitro long-term
expansion capacity from human ESCs or iPSCs with three
defined factors (c-MYC, BMI1, and BCL-XL) with a temporally hi-
erarchical overexpression protocol (Figures 2 and S3D–S3G).
Sustained expansion of these imMKCLs relied on carefully regu-
lated expression of the inducing genes to balance proliferative
and apoptotic signals and optimize consistent proliferation.
These self-replicating MKs may be applicable in the clinic as a(C) Numbers of CD41a+CD42b+ platelets generated from imMKCL Cl-2 (KhES3) a
genes off. Results are expressed as means ± SE from three independent experim
(D) Histograms show CD42b, CD49b, CD61, PAR1, GPVI, and CD29 expression o
and imMKCL Cl-2 and Cl-7. Donor-derived pooled platelets were pooled at 37
Pooled platelets were from donor 1. imMKCL platelets were from Cl-2 (yellow) and
y axes, counts.
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platelets.
We also showed that the INK4A/ARF and caspase 3 and 7
pathways are activated at the MK progenitor stage when
c-MYC levels are too high. The DD derived from mutant human
FKBP12 contributes to instability of the tagged protein, but the
effect is attenuated by addition of Shield1 (Banaszynski et al.,
2006). By using a DD tag vector system as a tool for investigating
the impact of restricted c-MYC levels (Figures 1E–1G and S1G),
we confirmed the importance of reducing caspase activity during
immortalized self-replication of theMK lineage in the presence of
TPO and SCF, which suggests that caspase activity plays a role
in the previously observed unstable proliferation of MKs in vitro
(Figures 7A–7C). This ‘‘constrained protein expression’’ system
could also be useful for studying genes that must be strictly regu-
lated. These findings also suggest the existence of a regulatory
pathway distinct from the INK4A/ARF and p53 pathways that ex-
erts a protective effect against oncogenic stress in the MK line-
age (Figure 2F).
Exogenous overexpression of BCL-XL contributed to long-
term self-replication by attenuating caspase 3 and 7 activation,
even in the presence of higher c-MYC levels (Figure 7C), and
endogenous BCL-XL may be required for the survival of
imMKCLs yielding platelets (Figures S5A and S5B). Consistent
with that idea, results obtained with BCL-XL-deficient mice indi-
cate that this protein is required for MK survival and platelet
release (Josefsson et al., 2011). By contrast, sustained BCL-XL
overexpression reportedly has a negative effect on the develop-
ment of demarcationmembranes inMKs and on platelet produc-
tion (Kaluzhny et al., 2002). However, c-MYC-dependent MK
proliferation was also TPO-dependent and required BMI1 to be
present prior to BCL-XL (Figures 1C, 2C, 2D, and S3D–S3G).
Interestingly, we recently showed that the combination of
c-MYC and BCL-XL overexpression in CD34+CD43+-containing
HPCs leads to stable erythroblast self-replication induced by
erythropoietin (Hirose et al., 2013) but not MK lineage growth
(Figure 1C). Thus, distinct combinations of c-MYC and BCL-XL
and c-MYC and BMI1 appear to provide context-dependent
expansion capacity for erythroblast or MK lineages, respectively
(Hirata et al., 2013; Yamamoto et al., 2013). It has also been
reported that BMI1 directly binds to RUNX1 and core binding
transcriptional factor b and acts as a regulator during megakar-
yopoiesis (Yu et al., 2012), suggesting that BMI1 may have
an alternative function in imMKCL development. The MK pro-
liferation program may be disrupted when the effects of BCL-
XL dominate before the MK proliferation program is fully
established.
For clinical application, the quality of expandable imMKCLs
must be strictly validated, and they must be cryopreserved as
master cell banks (MCBs) matched to the required HLA and
HPA type. After thawing, MCB-derived working cells would be
expected to grow within an appropriate and sufficient term andnd Cl-7 (DN-SeV2) in a 1 ml culture volume. White bars, genes on; black bars,
ents.
n platelets (fresh and pooled) derived from normal donors (two different donors)
C for 5 days. Fresh human platelets were from donors 1 (purple) or 2 (green).
Cl-7 (red). Black lines in all panels indicate IgG control. x axes, MFI (log scale);
Figure 5. Characterization of imMKCL-Derived Platelets In Vitro
(A) Transmission electron micrographs of an imMKCL Cl-7-derived platelet 5 days after genes off (left) and two fresh donor platelets (right). The imMKCL platelet
shows fewer a-granules and dense granules than fresh platelets. The scale bar represents 1 mm.
(B) Representative contour plots for imMKCL platelets showing CD42a (GPIX) and PAC1 bound in the absence or presence of thrombin (1 u/ml).
(C) PAC1 binding to human fresh platelets, human pooled platelets, or imMKCL platelets was quantified by flow cytometry. Data depict means (± SEM) from three
independent experiments. y axis indicatesDMFI calculated as agonist (+) minus no agonist (). TheMFI of agonist () was 1.0 in individual samples. ADP (200 mM)
or thrombin (1 u/ml) was the agonist.
(legend continued on next page)
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Platelets from Immortalized Megakaryocytesgenerate large numbers of platelets. In this context, continuous
culture after cryopreservation (Figure 2E) may enable a contin-
uous supply of platelets through gene manipulation (i.e., a
drug-induced genes-off condition). Furthermore, after we had
established stably expandable imMKCLs in the presence of
serum, we identified two clones that were capable of growing
well in liquid culture after adaptation to serum- and feeder-free
conditions (Figure S6D). This development suggests that it
may well be feasible to use this type of system to generate plate-
lets on the type of industrial scale that can be achieved with
tanks.
We compared our current imMKCL/MCB system with our
earlier strategy (Takayama et al., 2010). Figure S7 depicts the ad-
vantages of the current strategy and its feasibility in terms of
three parameters: manipulation, duration, and culture scale.
For each parameter in the figure, the top panels show our current
protocol, and the bottom panels show the earlier protocol (Ta-
kayama et al., 2010). It is important to consider the need to pre-
pare and provide more than 1011 platelets, given that 3 3 1011
platelets are required for 1 u of platelet concentrate for transfu-
sion in the United States. We suggest using 108 imMKCL cells
per vial as a MCB-derived working cell stock, which will produce
2.5 3 1010 MKs in around 14 days (Figures 2C, 2D, and S3D–
S3G). In addition, much less medium is required in the current
system (Figure S7), and theremight be no requirement for mouse
feeder cells or serum (Figure S6D). However, when looking at the
similarity between human endogenous platelets and imMKCL
platelets, there were several discrepancies between the func-
tional parameters in vitro and in vivo (Figures 6C and 6D). In gen-
eral, platelet concentrate is supplied in highly concentrated
serum for transfusion. This suggests that supplementing with
serum or a serum replacement could help to increase the func-
tional capacity of imMKCL-derived platelets. Our data already
suggest that this approach could be helpful; for example, serum
supplementation improved clot retraction with imMKCL-derived
platelets (Figure 5E). This is in contrast to endogenous pooled
platelets, which did not form clots at all, even with serum supple-
mentation. Therefore, although further optimization of this final
step is needed (e.g., through the induction of differentiation at
room temperature (20C –24C) before imMKCL platelets are
clinically useful, we conclude that an imMKCL system could
potentially provide useful platelets in large quantities.
As mentioned, another area for further optimization is the
platelet yield per MK, the improvement of which would
contribute to further reducing the volume. Several earlier reports(D) Flow cytometric detection of aggregated platelets as a double-positive pop
human fresh donor platelets (top panel in the dot plot) or with imMKCLs platele
stimulation. In the absence of agonist stimulation, the double-positive population
double-positive platelets (human fresh platelets, pooled platelets, or imMKCL p
minus agonist ().Results are expressed as means ± SE from seven independent
(right).
(E) Pictures of clot retraction. Human endogenous pooled or imMKCL (Cl-7) plat
cove’s modified Dulbecco’s medium (1.6 3 108 platelets/ml). Even when supplem
clot retraction, whereas imMKCL platelets did.
(F) Ex vivo flow chamber system within which human vWF (10 mg/ml) was immob
imMKCL Cl-2 and Cl-7 platelets were stained with carboxyfluorescein diacetat
rescence micrograph of the chamber. Bottom: relative number of CSFE+ plate
represents 100 mm. Results are expressed as means ± SE of a total of 20 trials
assigned as 1.0.
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limited efficiency of platelet production from single MKs (Ono
et al., 2012; Takayama et al., 2008, 2010). In contrast, it is
thought that each MK generates several thousand platelets
in vivo (Patel et al., 2005). One approach could be to use a biore-
actor that mimics the conditions within BM (Patel et al., 2005),
where shear stress from blood flow might accelerate platelet
biogenesis from MKs (Junt et al., 2007). On the basis of that
idea, we recently demonstrated the feasibility of an artificially
produced bioreactor with 2D microfluid circulation and biode-
gradable scaffolds, which increased platelet yield from hESC-
and hiPSC-derived MKs (Nakagawa et al., 2013).
In conclusion, the technology outlined in this study sheds light
on an exciting avenue for potential iPSC-based platelet supply.
This protocol is also being developed for an Investigational
New Drug Application to the United States Food and Drug
Administration. To achieve that, further optimization ofMKmatu-
ration and the efficiency of platelet release in a liquid culture sys-
tem will help to improve the technology as it develops toward
clinical application. Ultimately, we believe that, through the inte-
gration of a broad range of technologies, it will be feasible
through to achieve clinically effective platelet transfusion without
a requirement for donor blood.
EXPERIMENTAL PROCEDURES
Ethical Review
KhES-3 hESC clone (Institute for Frontier Medical Science, Kyoto University)
was used with approval from the Ministry of Education, Culture, Sports, Sci-
ence and Technology of Japan. Collection of PB from healthy volunteers
was approved by the ethics committee of the Institute of Medical Science at
the University of Tokyo and the Kyoto University Committee for Human Sam-
ple-Based Experiments. All studies involving the use of human samples were
conducted in accordance with the Declaration of Helsinki.
Cells, Reagents, and Mice
KhES-3 hESCs from H. Suemori (Suemori et al., 2006) and human iPSC clones
(585A1, 585B1, 606A1, 648B1, 692D2, and DNSeV-2) were used (Okita et al.,
2013). Six-week-old NOG mice were purchased from the Central Institute for
Experimental Animals. The mice were irradiated at 2.4 Gy in order to induce
thrombocytopenia 9 days before transfusion. Then, selected mice (platelets =
5–20 3104/ml) were used for studies of posttransfusion platelet kinetics and
in vivo imaging of thrombogeneity.
The following vectors were used: pMXs retroviral vector, pGCDNsam retro-
viral vector, modified pMXs Tet off-inducible retroviral vector (Ohmine et al.,
2001), and CSII-based all-in-one inducible lentiviral vector (Ai-LV) (Takayama
et al., 2010). Retrovirus production with a 293 Gag, Pol, VSV-G (vesicular sto-
matitis virus G) system and lentiviral production were as described previouslyulation among human fresh donor platelets stained with CD9-APC or among
ts (bottom panel in the dot plot) stained with CD9 Pacific Blue after agonist
was small. The lower graph contains summarized results showing the percent
latelets). y axis indicates D-aggregated percentage calculated as agonist (+)
experiments for ADP&TRAP (left) or four independent experiments for collagen
elets were suspended in 20% platelet-depleted human plasma containing Is-
ented with human plasma, pooled platelets stored without serum showed no
ilized, and the shear rate was 1,600 s1. Human and mouse PB platelets and
e, succinimidyl ester (CSFE) and analyzed. Top: representative immunofluo-
lets adhering to human vWF. HIP-1, human CD42b antibody. The scale bar
from three independent experiments. The mean value of human platelets is
Figure 6. imMKCL-Derived Platelets Show Circulation Potential and Intact In Vivo Functionality in a Thrombocytopenic Mouse Model
(A) Platelet transfusion model in which NOG mice were irradiated (2.4 Gy) in order to induce thrombocytopenia. Nine days later, imMKCL-derived platelets (6 3
108 or 1 3 108) and human PB-derived platelets (1 3 108) were injected via the tail vein. Shown are representative contour plots of samples from a transfused
mouse. Detected are mouse CD41+ and human CD41a+ cells 30 min, 2 hr, and 24 hr after transfusion.
(B) Platelet chimerism was quantified by flow cytometry. Circulation of injected platelets was evaluated after 30 min, 2 hr, and 24 hr. N = 4 individual groups from
two independent experiments.
(legend continued on next page)
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Figure 7. Models of MKCL Self-Replication Systems
(A) Excessive c-MYC induces strong activation of caspase 3 and 7 and
apoptotic pathways, despite the suppression of INK4A/ARF by ectopic BMI1,
leading to no self-replication.
(B) Appropriate activation of c-MYC induces a relatively low level of caspase 3
and 7 activation, leading to limited self-replication.
(C) Added BCL-XL acts in concert with BMI1 to suppress c-MYC-related
apoptotic pathways, leading to MKCL immortalization.
Cell Stem Cell
Platelets from Immortalized Megakaryocytes(Eto et al., 2007; Takayama et al., 2010). We amplified the DD-encoding
sequence from pPTunerC vector and Shield1 (Clontech and Takara Biotech-
nology) to generate the cMYC-DD construct. Shield1 was used to block DD-
domain-mediated protein degradation. The use of viral vectors was approved
by committees at the University of Tokyo or Kyoto University.
Cell Culture
On day 14 of culture, during hematopoietic differentiation from hESCs and
hiPSCs (Takayama et al., 2008), HPCs were collected and transferred
onto irradiated C3H10T1/2 cells in the presence of 50 ng/ml human SCF
(R&D Systems) and 50 ng/ml human TPO (R&D) (Takayama et al., 2010).
Gene expression was controlled by the presence or absence of 2 mM(C) Time-lapse confocal microscopy showing potential in vivo platelet function. M
representative sequential images showing initial adhesion by imMKCL-derived pla
green) along with dextran (Texas Red) are shown. Bottom: the number of initially
shown in Movie S2. The results are averaged data from 40 vessels from three to fiv
human P-selectin antibody. The scale bar represents 10 mm.
(D) Representative sequential images showing thrombus formation by imMKCL
platelets (green) along with dextran (Texas Red) are shown. Hematoporphyrin w
injury. Platelets adhered to the site of laser injury, finally contributing to the comp
bars represent 10 mm.
(E) Fresh donor platelets, pooled donor platelets, and imMKCL-derived platelet
5 days at 37C. Platelets from imMKCL Cl-1, Cl-2, Cl-3, and Cl-7 were used. The
five animals for each group). N.S., not significant; ***p < 0.001, ****p < 0.0001.
546 Cell Stem Cell 14, 535–548, April 3, 2014 ª2014 Elsevier Inc.b-estradiol or 1 mg/ml doxycycline (Clontech) for modified pMXs inducible
vector or the presence of 1mg/ml doxycycline for Ai-LV, respectively.MKdiffer-
entiation from CB CD34+ cell was accomplished as described previously
(Proulx et al., 2004).
In Vitro Analysis of imMKCLs, imMKCL Platelets, and Human
Platelets
qRT-PCR, cell-surface markers of imMKCLs and platelets, electron micro-
scopy, and PAC-1 binding were examined as described previously
(Takayama et al., 2010). Flow-cytometry-based platelet aggregation assays
were performed as described previously (De Cuyper et al., 2013). Clot retrac-
tion assays were carried out as described previously (Takizawa et al., 2010).
An ex vivo flow chamber precoated with human vWF (10 mg/ml, provided by
K. Soejima, Kaketsuken) was utilized to observe shear (1,600 s1)-dependent
thrombus formation under an inverted microscope equipped with fluores-
cence (Nikon A1R) and microfluid systems (Ibidi Products). Platelets were
stained with CFSE dye (5 mM, Invitrogen) and used in the presence of
CD42b (HIP1; Abcam; 10 mg/ml) or isotype-matched antibodies (BioLegend).
Human pooled platelets were prepared by 5-day culture at 37C under
serum-free conditions.
In Vivo Analysis in Mice
Nine days later, irradiation in NOG mice, fresh or pooled human platelets
from a donor, or imMKCL-derived platelets were intravenously administered
(100 ml). Then, blood samples (50–100 ml) were collected from the retro-
orbital plexus in the mice 30 min, 2 hr, and 24 hr after transfusion. The sam-
ples were labeled with human CD41a-APC and mouse CD41-PE antibodies
(EMFRET Analytics), after which chimerism was analyzed. Similar NOG mice
with thrombocytopenia were also used for in vivo imaging studies. To visu-
ally analyze thrombus formation in the microcirculation of the mesentery in
living animals, we used in vivo laser- and reactive-oxygen-species-induced
injury with a visualization technique developed through modification of con-
ventional methods (Nishimura et al., 2012; Takizawa et al., 2010). Some ex-
periments were performed with AK4 (human P-selectin antibody; Abcam;
20 mg/ml). Additional details of the methods and other information for imag-
ing are presented in the Supplemental Information.
Statistical Analysis
All data are presented as means ± SEM. The statistical significance of the
observed differences was determined with one-way ANOVA followed by
Tukey’s multiple comparison test and two-tailed Student’s t tests for pairwise
comparisons. Values of p < 0.05 were considered significant.
ACCESSION NUMBERS
Raw and normalized microarray data have been deposited in the NCBI Gene
Expression Omnibus database under accession number GSE54168.
SUPPLEMENTAL INFORMATION
Supplemental Information contains Supplemental Experimental Procedures,
seven figures, and three movies and can be found with this article online at
http://dx.doi.org/10.1016/j.stem.2014.01.011.ice were transfused with 1 3 108 platelets derived from different groups. Top:
telets onto injured vessel walls. CSFE-labeled imMKCLplatelets (Cl-2 and Cl-7;
attached platelets per 100 mm vessel length were counted. Actual results are
e animals in each group. N.S., not significant; ***p < 0.001, ****p < 0.0001. AK4;
-derived platelets within a small capillary and artery. CSFE-labeled imMKCL
as administrated in order to induce thrombus formation prior to laser-induced
lete occlusion of vessels. Original videos are available as Movie S3. The scale
s incorporated into thrombi were quantified. Pooled platelets were stored for
results summarize four independent experiments (n = 40 vessels from three to
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